Active — Not RecruitingPhase 3

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

United States296 participantsStarted 2017-04-27

Plain-language summary

A phase 3 study to demonstrate whether lorlatinib given as monotherapy is superior to crizotinib alone in prolonging the progression-free survival in advanced ALK-positive NSCLC patients who are treatment naïve and to compare lorlatinib to crizotinib with respect to overall survival in the same population

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. known strong CYP3A inhibitors .
✕. known strong CYP3A inducers
✕. known P gp substrates with a narrow therapeutic index

What they're measuring

Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) Assessment

Timeframe: From time of Study Start up to 33 months

Trial details

NCT IDNCT03052608

SponsorPfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2020-03-20

Results submitted2021-03-05

View on ClinicalTrials.gov More Carcinoma, Non-Small-Cell Lung trials